Merial, a global leader in avian vaccines, is recognizing an important 10-year milestone of protecting flocks against Marek's disease and Gumboro disease, also known as Infectious Bursal Disease. Since the introduction of VAXXITEK HVT+IBD in Brazil in 2006, the vaccine has protected more than 70 billion birds across more than 75 countries against these two critical diseases, for which no treatment exists, considerably simplifying the vaccination process and contributing to disease prevention and efficiency strategies for poultry production businesses worldwide.
“We are extremely proud of the contributions of VAXXITEK HVT+IBD to poultry health in countries globally,” said Jérôme Baudon, Global Head of the Avian Business at Merial. ”It is one of the most used poultry vaccines in the world, and when it was introduced 10 years ago, Merial truly invented a new category by allowing for immunization against two diseases with a single vaccine dose given in the hatchery.”
Marek’s and Gumboro diseases are two of the most common, contagious and significant immunosuppressive viral diseases in poultry. In light of the growing need for protein in the world, innovative poultry health solutions, including VAXXITEK HVT+IBD, are critical to enhance poultry disease prevention, production and cost efficiencies. By 2020, chicken is expected to overtake pork as the global animal protein of choice.
VAXXITEK HVT+IBD continues to represent a significant advance in vaccination, with only one single application for each bird. The vector-based vaccine is administered subcutaneously to one day old chicks or in-ovo (in the egg) in the hatchery. This approach enables continuity of protection against Marek’s Disease and IBD before chicks are placed on the farm, removing doubts about the right timing of vaccination, and also improving the consistency of quality vaccine delivery. In addition, VAXXITEK HVT+IBD provides proven protection against a wide variety of IBD field strains without inducing bursa lesions or immunosuppression.